IFI16 is an exclusive host sensor protein associated in the EBV infection cycle evincing it a prospective therapy to fight EBV‐related infections, IFI16 expression in p16 therapy, Anti‐IFI16 IgG antibodies in infliximab (IFX) therapy, IFI16 in hepatocellular carcinoma (HCC) therapy. This evidence concerns the gene CDKN2A and hepatocellular carcinoma.